LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Начало・Списък с акции・Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

638.17 -0.53

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

633.36

Максимум

642.52

Ключови измерители
By Trading Economics
Приходи	-117M 727M
Продажби	-279M 3.6B
P/E Средно за сектора	15.384 49.701
EPS	9.47
Дивидентна доходност	0.51
Марж на печалбата	20.17
Служители	15,343
EBITDA	-234M 967M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+29.13% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	0.51% 2.39%
Следващи печалби	31.07.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-12B 66B
Предишно отваряне	638.7
Предишно затваряне	638.17

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

542.44 / 599.76 Подкрепа & съпротива

Regeneron Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

1.08.2025 г., 11:33 ч. UTC

Печалби

Regeneron 2Q Revenue, Adjusted EPS Top Estimates

29.04.2026 г., 12:01 ч. UTC

Печалби

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

23.04.2026 г., 21:48 ч. UTC

Придобивния, сливания и поглъщания

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

11.03.2026 г., 11:02 ч. UTC

Пазарно говорене

Sanofi, Regeneron's Eczema Drug Might Face Competition From Pfizer -- Market Talk

14.12.2025 г., 08:30 ч. UTC

Придобивния, сливания и поглъщания

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

1.08.2025 г., 13:16 ч. UTC

Печалби

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1.08.2025 г., 12:40 ч. UTC

Печалби

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1.08.2025 г., 10:41 ч. UTC

Печалби

Regeneron Now Sees 2025 Adjusted R&D $5.1B-$5.2B; Had Seen $5B-$5.2B >REGN

1.08.2025 г., 10:41 ч. UTC

Печалби

Regeneron Now Sees 2025 Capital Spending $880M-$950M; Had Seen $850M-$950M >REGN

1.08.2025 г., 10:40 ч. UTC

Печалби

Regeneron Now Sees 2025 Adjusted Gross Margin on Net Product Sales About 86%; Had Seen 86%-87% >REGN

1.08.2025 г., 10:38 ч. UTC

Печалби

Regeneron: Odronextamab Application Also Impacted by Site Inspection >REGN

1.08.2025 г., 10:37 ч. UTC

Печалби

Regeneron Gets FDA Complete Response Letter for Odronextamab in Follicular Lymphoma >REGN

1.08.2025 г., 10:35 ч. UTC

Печалби

Regeneron: Anticipate Expeditious Resolution of Filling Issues for Eylea HD >REGN

1.08.2025 г., 10:34 ч. UTC

Печалби

Regeneron Cites Observations From FDA General Site Inspection at Filler for Eylea HD >REGN

1.08.2025 г., 10:33 ч. UTC

Печалби

Regeneron Sees FDA Approvals Delayed for Eylea HD Indications With August Target Actio Dates >REGN

1.08.2025 г., 10:32 ч. UTC

Печалби

Regeneron Pharma: About 45 Product Candidates in Clinical Development >REGN

1.08.2025 г., 10:31 ч. UTC

Печалби

Regeneron Pharma 2Q Eylea HD, Eylea U.S. Net Sales Fell 25% to $1.15B >REGN

1.08.2025 г., 10:31 ч. UTC

Печалби

Regeneron Pharma: 2Q Dupixent Global Net Sales Recorded by Sanofi Rose 22% to $4.34B >REGN

1.08.2025 г., 10:30 ч. UTC

Печалби

Regeneron Pharma 2Q Adj EPS $12.89 >REGN

1.08.2025 г., 10:30 ч. UTC

Печалби

Regeneron Pharma 2Q Rev $3.68B >REGN

1.08.2025 г., 10:30 ч. UTC

Печалби

Regeneron Pharma 2Q EPS $12.81 >REGN

1.08.2025 г., 10:30 ч. UTC

Печалби

Regeneron Pharma 2Q Net $1.39B >REGN

13.06.2025 г., 21:42 ч. UTC

Придобивния, сливания и поглъщания

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

13.06.2025 г., 20:45 ч. UTC

Придобивния, сливания и поглъщания

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

13.06.2025 г., 20:34 ч. UTC

Придобивния, сливания и поглъщания

Anne Wojcicki Wins Bidding for 23andMe -- Update

13.06.2025 г., 20:14 ч. UTC

Придобивния, сливания и поглъщания

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

13.06.2025 г., 20:14 ч. UTC

Придобивния, сливания и поглъщания

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

13.06.2025 г., 20:14 ч. UTC

Придобивния, сливания и поглъщания

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

5.06.2025 г., 01:41 ч. UTC

Придобивния, сливания и поглъщания

23andMe's Former CEO Pushes Purchase Price Nearly $50 Million Higher -- WSJ

30.05.2025 г., 08:58 ч. UTC

Горещи акции

Stocks to Watch Friday: Dell, Marvell, Gap, Ulta -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Regeneron Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

29.13% нагоре

12-месечна прогноза

Среден 829.77 USD 29.13%

Висок 995 USD

Нисък 641 USD

Според 22 анализатори от Wall Street, предложили 12-месечна ценова цел за Regeneron Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

22 ratings

Купи

Задържане

Продай

Според 22 анализатори, дали борсови рейтинги на Regeneron Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

542.44 / 599.76Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.